Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Pancreatic Neoplasms 5Recurrence 2Neoplasms 2Carcinoma, Merkel Cell 2Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Pharmacokinetics 1Ovarian Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Squamous Cell 1Breast Neoplasms 1Advanced Triple Negative Breast Cancer 1

Interventions

Rituximab 30Cyclophosphamide 18fludarabine phosphate 14Filgrastim 12Mycophenolic Acid 11Antilymphocyte Serum 11Cyclosporine 10Whole-Body Irradiation 9Bortezomib 9Tacrolimus 8Radiotherapy 8Peripheral Blood Stem Cell Transplantation 8Methotrexate 6Lenalidomide 6Cord Blood Stem Cell Transplantation 6Busulfan 6Granulocyte Colony-Stimulating Factor 5venetoclax 4tanespimycin 4Polymerase Chain Reaction 4Methylprednisolone 4Melphalan 4Flow Cytometry 4Etoposide 4Bendamustine Hydrochloride 4ublituximab 3thymoglobulin 3pembrolizumab 3ibritumomab tiuxetan 3fludarabine 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Lymphoma, B-Cell, Marginal Zone × ALT-803 × Clear all
NCT02384954 2024-07-03

QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab

Altor BioScience

Phase 1/2 Terminated
43 enrolled 15 charts
LymphoidOther hematologic neoplasm

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡